OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. has four anti-cancer therapeutic candidates: Navicixizumab, which is a bispecific monoclonal antibody that targets and inhibits both Delta-like ligand 4, and vascular endothelial growth factor; Anti-TIGIT, which is an inhibitory receptor that stops T-cells from attacking certain tumor cells; GITRL-Fc, which is engineered using a single-gene, linkerless trimer technology that is designed to enable activation of glucocorticoid-induced tumor necrosis factor receptor-related protein; and Rosmantuzumab, which is a monoclonal antibody targeting the RSPO-LGR cancer stem cell pathway. We show 23 historical shares outstanding datapoints in our OMED shares outstanding history coverage, used to compute OMED market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing OMED market cap history over the course of time is important for investors
interested in comparing OMED's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of OMED versus a peer is one thing; comparing
OMED market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like OMED can fluctuate over the course of history.
With this page we aim to empower investors researching OMED by allowing them to research the OMED market cap history. |
Free OMED Email Alerts:
Video: The Importance of Market Cap
